Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The form provides key information about the dealings of the exempt principal trader with recognized intermediary status. The form states that Panmure Gordon (UK) Limited made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares on August 24, 2023. The form also mentions that there were no cash-settled derivative transactions or stock-settled derivative transactions (including options) involving Allergy Therapeutics' securities. Additionally, there were no other dealings, such as subscribing for new securities, mentioned in the form.

The form does not provide any information about the reasons behind the purchases and sales of Allergy Therapeutics' shares by Panmure Gordon (UK) Limited. It is important to note that the form does not include any regulatory, contact, or general risk information.

Overall, the provided news is a regulatory disclosure form that highlights the dealings of Panmure Gordon (UK) Limited with Allergy Therapeutics' securities.